logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10457669 B1

PDFFull Text
Date of Patent:
Oct. 29, 2019

Filed:

Oct. 20, 2016

Benzolactam compounds as protein kinase inhibitors

Applicant:

Otsuka Pharmaceutical Co., Ltd., Tokyo, JP;

Inventors:

Valerio Berdini, Cambridge, GB;

Ildiko Maria Buck, London, GB;

James Edward Harvey Day, Cambridge, GB;

Charlotte Mary Griffiths-Jones, Cambridge, GB;

Thomas Daniel Heightman, Harpenden, GB;

Steven Howard, Cambridge, GB;

Christopher William Murray, Cambridge, GB;

David Norton, Cambridge, GB;

Marc O'Reilly, Hereford, GB;

Alison Jo-Anne Woolford, Cambridge, GB;

Michael Liam Cooke, Nottingham, GB;

David Cousin, Nottingham, GB;

Stuart Thomas Onions, Nottingham, GB;

Jonathan Martin Shannon, Nottingham, GB;

John Paul Watts, Southwell, GB;

Assignee:

OTSUKA PHARMACEUTICAL CO., LTD., Tokyo, JP;

Attorney:

Heslin Rothenberg Farley & Mesiti P.C.

Primary Examiner:

John M Mauro

Int. Cl.
CPC ...
C07D 405/14 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01); C07D 403/14 (2006.01); C07D 409/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 471/08 (2006.01); C07D 403/04 (2006.01); C07D 487/04 (2006.01); C07D 497/08 (2006.01); C07D 498/22 (2006.01); C07D 513/04 (2006.01); A61P 35/00 (2006.01); A61K 31/444 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 31/55 (2006.01); A61K 31/553 (2006.01);
U.S. Cl.
CPC ...
C07D 405/14 (2013.01); A61K 31/444 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/55 (2013.01); A61K 31/553 (2013.01); A61P 35/00 (2018.01); C07D 403/04 (2013.01); C07D 403/14 (2013.01); C07D 409/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 497/08 (2013.01); C07D 498/22 (2013.01); C07D 513/04 (2013.01);
Abstract

The invention provides a compound of formula (0): The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.

Find Patent Forward Citations

Loading…